Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO_RSTAP: Medial TAP and Rectus Sheath Blocks in Inguinal Hernia Surgery Recovery
2024-513406-59-00Phase 3Authorised
- Sponsor
- Pirkanmaan hyvinvointialue
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in inguinal hernia comparing Ropivacaine medial TAP + rectus sheath block with Placebo (NaCl 0.9%) medial TAP + rectus sheath block (2 arms). Primary endpoint: Equivalent morphine consumption in the perioperative period and after surgery. Planned start Nov 2024; status: authorised.
02
Drugs
ropivacaine
03
Conditions
inguinal hernia
Beyond the preview
Go deeper on 2024-513406-59-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513406-59-00.